A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain

Journal of Pain and Symptom Management

Volumn 16, Issue 2, 1998, Pages 102-111

  Sloan, Paul A ^a   Moulin, Dwight E ^b   Hays, Helen ^c  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Misericordia Community Hospital   (Canada)

Author keywords

Cancer pain; Opioid analgesia; Opioid side effects; Transdermal fentanyl

Indexed keywords

ANALGESIC AGENT; ANILERIDINE; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CODEINE; FENTANYL; HALOPERIDOL; HYDROMORPHONE; HYPNOTIC AGENT; METOCLOPRAMIDE; MORPHINE; MORPHINE SULFATE; PARACETAMOL; PROCHLORPERAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CANCER PAIN; CLINICAL TRIAL; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PATIENT SATISFACTION; RASH; TRANSDERMAL DRUG ADMINISTRATION; VOMITING;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC DISEASE; EVALUATION STUDIES; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PROSPECTIVE STUDIES;

EID: 0032143867     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(98)00044-X     Document Type: Article

References (28)

1. 1. Jacox AK, Carr DB, Payne R. Management of cancer pain. Clinical practice guideline no. 9. Agency for Healthcare Policy and Research publication no. 94-0592 Rockfield, MD: Agency for Healthcare Policy and Research, 1994.
2. 2. Warren DE. Practical use of rectal medications in palliative care. J Pain Symptom Manage 1996;11: 378-387.
3. 3. Portenoy RK, Southam MA, Gupta SK, et al. Transdermal fentanyl for cancer pain: repeated dose pharmacokinetics. Anesthesiology 1993;78:36-43.
4. 4. Korte W, de Stoutz N, Morant R. Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short-and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 1996;11:139-146.
5. 5. Payne R. Experience with transdermal fentanyl in advanced cancer. Eur J Pain 1990;11:98-101.
6. 6. Herbst LH, Strause LG. Transdermal fentanyl use in hospice home-care patients with chronic cancer pain. J Pain Symptom Manage 1992;7(suppl 3), S54-S57.
7. 7. Zech DF, Lehmann KA, Grond S. A new treatment option for chronic cancer pain. Eur J Palliat Care 1994;1:26-30.
8. 8. Miser AW, Narang PK, Dothage JA, Young RC, Sindelar W, Miser JS. Transdermal fentanyl for pain control in patients with cancer. Pain 1989;37:15-21.
9. 9. Zech DF, Grond SU, Lynch J, et al. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 1992;50:293-301.
10. 10. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64:527-534.
11. 11. Fainsinger RL, Bruera E. How should we use transdermal fentanyl (TF) for pain management in palliative care patients? J Palliat Care 1996;12:48-53.
12. 12. Sloan PA, Donnelly MB, Schwartz RW, Sloan DA. Cancer pain assessment and management by housestaff. Pain 1996; 67:475-481.
13. 13. Hanks GW, Fallon MT. Transdermal fentanyl in cancer pain: conversion from oral morphine [Letter]. J Pain Symptom Manage 1995;10:87.
14. 14. Grond S, Zech D, Lehmann KA, Rodlorch L, Breitenbach H, Hertel D. Transdermal fentanyl in the long-term treatment of cancer pain a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 1997;69:191-198.
15. 15. DeSio JM, Bacon DR, Peer G, Lema MJ. Intravenous abuse of transdermal fentanyl therapy in a chronic pain patient. Anesthesiology 1993;79:1139-1141.
16. 16. Rose PG, Macfee MS, Boswell MV. Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. Anesth Analg 1993;77:390-391.
17. 17. Ashburn MA, Fine PG, Stanley TH. Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: a case report. Anesthesiology 1989;71:615-617.
18. 18. Thirlwell MP, Sloan PA, Maroun JA, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989;65:2275-2283.
19. 19. Dhaliwal HS, Sloan P, Arkinstall WW, et al. Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain. J Pain Symptom Manage 1995;10:612-623.
20. 20. Bruera E, Sloan P, Mount B, Scott J, Suarez-Almazor M. A randomized, double-line, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. J Clin Oncol 1996;14:1713-1717.
21. 21. Sloan PA, Melzack R. Long-term patterns of morphine dosage and pain intensity in cancer patients. Can J Anesth 1995;42:A37-B.
22. 22. Hammack JE, Mailliard JA, Loprinzi CL, et al. Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study. J Pain Symptom Manage 1996;12:234-240.
23. 23. Von Roenn JH, Cleeland CS, Gonin R, Hatfield AK, Pandya KJ. Physician atttitudes and practice in cancer pain management. Ann Intern Med 1993; 119:121-126.
24. 24. Higgs CM, Vella-Brincat J. Withdrawal with transdermal fentanyl [Letter]. J Pain Symptom Manage 1995;10:4-5.
25. 25. Savage SR. Long-term opioid therapy: assessment of consequences and risks. J Pain Symptom Manage 1996;11:274-286.
26. 26. Santillan R, Maestre JM, Hurle MA, Florez J. Enhancement of opiate analgesia by nimodipine in cancer patients chronically treated with morphine: a preliminary report. Pain 1994;58:129-132.
27. 27. Foley KM. Clinical tolerance to opioids. In: Basbaum AI, Besson JM, eds. Towards a new pharmacotherapy of pain. John Wiley and Sons Ltd, 1991:181-203.
28. 28. Ashburn MA, Lipman A. Management of pain in the cancer patient. Anesth Analg 1993;76:402-416.